AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.38

High:0.600

Open:0.600

Low:0.600

Close:0.600

Loading ...

Overview Company News Filings

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

This ASX share potentially 'has no value from here', says broker

Hearts and Minds Investments Writes Down Opthea Holding to Zero

MT Newswires Live

Market Chatter: Regal Takes Responsibility for Opthea Investment Losses

MT Newswires Live

Opthea Ends Development of Sozinibercept in Wet AMD

Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials

MT Newswires Live

BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD Trials

Opthea Announces Decision to Discontinue Wet Amd Trials

THOMSON REUTERS

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Ltd - Estimates Will Have Unaudited Cash and Cash Equivalents of US$100M at End of March 2025

THOMSON REUTERS

Opthea Ltd - There Remains Material Uncertainty as to Opthea's Ability to Continue as a Going Concern

THOMSON REUTERS

Why this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'

Australian Shares Rise as Trump Signals Tariff Leniency; Endeavour to Undergo Overhaul as New Executive Chairman Leads Review

MT Newswires Live

HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%

MT Newswires Live

Trading in Opthea Still Halted After Phase 3 Study Failure

Opthea Ltd : H.c. Wainwright Cuts Target Price to $2 From $12

THOMSON REUTERS

BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake

Opthea Ltd : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $12

THOMSON REUTERS

Regal Confirms Stake in Opthea

MT Newswires Live

Opthea Announces Coast Phase 3 Trial Topline Results

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1743743520000,"preClose":0.6,"halted":0,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786004505,"shares":1231284320,"eps":-0.4354509349660765,"marketStatus":"Market Closed","change":0,"latestTime":"04-04 16:12:00 AEDT","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.4354509349660765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1743984000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1743721200000,1743742800000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786004505,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.571069,"shares":1231284320,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.65","psRate":"2137.51","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.4354509349660765,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.4354509349660765,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.7,"sixtyDayClose":0.745},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525222758","title":"Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2525222758","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525222758?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"ASX share Opthea Limited (ASX: OPT)remains suspended from trading as the biotechcompany works to avoid insolvency.  Opthea last traded at 60 cents per share.   Last week, we learned that Opthea has de","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/05/broker-laments-catastrophic-negative-surprise-that-highlights-the-risks-with-these-types-of-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7511","MSB.AU","BK7067","BK7508","CSL.AU","OPT.AU","BK4139","OPT","XJO.AU","BK7501"],"gpt_icon":0},{"id":"2524227858","title":"This ASX share potentially 'has no value from here', says broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2524227858","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524227858?lang=en_us&edition=fundamental","pubTime":"2025-04-04 12:55","pubTimestamp":1743742507,"startTime":"0","endTime":"0","summary":"The ASX biotech advised investors on 24 March that its Phase 3 COAST clinical trial of OPT-302 had failed to meet its primary endpoint.  The trial was assessing sozinibercept  combined with aflibercept to treat wet AMD. The failure of the trial raised serious financial concerns for Opthea. The company said it would review its obligations under its Development Funding Agreement  with key investors to decide the next steps.  What's the latest news with this ASX biotech share?Importantly, Opthea and its DFA investors have agreed that ceasing both trials does not constitute a 'termination event' under the DFA. This means Opthea does not","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/this-asx-share-potentially-has-no-value-from-here-says-broker/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","OPT","LU2264538146.SGD","LU1852331112.SGD","LU2458330243.SGD","BK7067","BK4612","BK4512","LU0979878070.USD","LU0082616367.USD","LU0719512351.SGD","LU1064131342.USD","LU1989764664.SGD","LU0056508442.USD","IE00B5949003.HKD","LU1951198990.SGD","IE0009356076.USD","LU0198837287.USD","LU0109392836.USD","LU0642271901.SGD","BK4585","BK4534","BK4573","LU1880398471.USD","LU2054465674.USD","BK4566","LU0127658192.USD","LU0390134368.USD","LU1303367103.USD","LU1242518931.SGD","OPT.AU","LU0823434740.USD","BK7508","LU2458330169.SGD","IE00BMPRXR70.SGD","LU1951200564.SGD","BK4575","LU0823421333.USD","LU0823434583.USD","LU1803068979.SGD","BK4605","LU1988902786.USD","GFS","BK4141","LU2360106780.USD","BK4529","LU1316542783.SGD","BK4588","IE0004445239.USD"],"gpt_icon":1},{"id":"2524548879","title":"Hearts and Minds Investments Writes Down Opthea Holding to Zero","url":"https://stock-news.laohu8.com/highlight/detail?id=2524548879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524548879?lang=en_us&edition=fundamental","pubTime":"2025-04-02 12:03","pubTimestamp":1743566613,"startTime":"0","endTime":"0","summary":"Hearts and Minds Investments  said its board decided to write down the value of its portfolio holding in Opthea  to zero, effective Monday, according to a Wednesday Australian bourse filing.The board had previously written down the value of the holding to AU$0.20 per share.The write-down will negatively impact the net asset value of the firm by around AU$0.034 per share, the filing said.This move comes after Opthea said that its second phase three trial of a treatment for an eye disease had failed.Hearts and Minds Investments' shares jumped past 1% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OPT","BK7508","BK4139","OPT.AU","HM1.AU"],"gpt_icon":0},{"id":"2524177853","title":"Market Chatter: Regal Takes Responsibility for Opthea Investment Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2524177853","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524177853?lang=en_us&edition=fundamental","pubTime":"2025-04-02 09:23","pubTimestamp":1743557031,"startTime":"0","endTime":"0","summary":"Regal Investment Fund  Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea , the Australian Financial Review reported Wednesday, citing a letter to investors.Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","OPT.AU","RF1.AU","BK4139","BK7067","BK7508"],"gpt_icon":0},{"id":"2523420469","title":"Opthea Ends Development of Sozinibercept in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2523420469","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523420469?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:37","pubTimestamp":1743428220,"startTime":"0","endTime":"0","summary":"Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study.Opthea on Monday said its second Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision, missed its primary endpoint of mean change in best corrected visual acuity.The clinical-stage biopharmaceutical company said it opted to accelerate the study readout following the similar Phase 3 study failure it reported last week.Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the funding deal.However, the company warned once again that it might be required to pay amounts to the investors--which would have a material adverse effect on its solvency--and that there is material uncertainty about its ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU1951198990.SGD","BK4139","BK4512","IE0004445239.USD","LU1242518931.SGD","LU0109392836.USD","LU0823421333.USD","LU0823421416.USD","BK4543","BK4532","GFS","IE00BMPRXR70.SGD","BK4529","BK4575","LU0082616367.USD","LU0979878070.USD","LU1803068979.SGD","LU0823434740.USD","LU1923623000.USD","BK4573","BK4605","IE0009356076.USD","LU1242518857.USD","LU0198837287.USD","LU0823434583.USD","IE00BMPRXN33.USD","LU1064131342.USD","LU2458330169.SGD","IE00B5949003.HKD","BK4585","LU0081259029.USD","LU1316542783.SGD","LU0127658192.USD","LU1880398554.USD","LU1989764664.SGD","BK4534","LU2264538146.SGD","LU2458330243.SGD","OPT.AU","BK7508","LU0889565833.HKD","OPT","LU2250418816.HKD","LU2054465674.USD","LU0056508442.USD","LU1988902786.USD","LU2098885051.SGD","BK4588"],"gpt_icon":1},{"id":"2523956912","title":"Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523956912","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523956912?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:58","pubTimestamp":1743418697,"startTime":"0","endTime":"0","summary":"Opthea  said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.The ASX will susp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK7508","BK7067","BK4139","OPT"],"gpt_icon":0},{"id":"2523993026","title":"BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523993026","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523993026?lang=en_us&edition=fundamental","pubTime":"2025-03-31 16:34","pubTimestamp":1743410051,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD TrialsMarch 31  - Opthea Ltd OPT.AX:ANNOUNCES DECISION TO DISCONTINUE WET AMD TRIALSCONTINUES ACTIVE DISCUSSIONS WITH DFA INVESTORSESTIMATES WILL HAVE UNAUDITED CASH AND CASH EQUIVALENTS OF US$100M AT END OF MARCH 2025THERE REMAINS MATERIAL UNCERTAINTY AS TO OPTHEA'S ABILITY TO CONTINUE AS A GOING CONCERNFurther company coverage: OPT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OPT.AU"],"gpt_icon":0},{"id":"2523951211","title":"Opthea Announces Decision to Discontinue Wet Amd Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523951211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523951211?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:01","pubTimestamp":1743393660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUABKBNM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2523951735","title":"Opthea Announces Decision to Discontinue Wet AMD Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523951735","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523951735?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:01","pubTimestamp":1743393660,"startTime":"0","endTime":"0","summary":"ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea and DFA Investors agreed to terminate both COAST and ShORe trials. Opthea continues to consider impact of negative trial results under its Development Funding Agreement  and on the Company as a going concern. The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks, as per label, versus 0.5 mg ranibizumab monotherapy. The trial did not meet its primary endpoint of mean change in best corrected visual acuity  from baseline to week 52.“We are disappointed that COAST and ShORe did not demonstrate the improvements in vision with sozinibercept combination therapy compared to standard of care that we had hoped for,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “We are grateful to all patients, clinica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-announces-decision-discontinue-wet-040100489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4573","BK4529","BK4612","LU0979878070.USD","LU0889565833.HKD","IE00B5949003.HKD","LU1803068979.SGD","BK4512","LU2098885051.SGD","BK4614","LU1989764664.SGD","LU2250418816.HKD","LU0719512351.SGD","LU1988902786.USD","IE00BMPRXN33.USD","BK4141","LU0823434740.USD","BK4585","LU1303367103.USD","BK4554","IE00BMPRXR70.SGD","OPT","LU0823421416.USD","LU0082616367.USD","GFS","LU1064131342.USD","LU1951200564.SGD","LU2458330169.SGD","LU0823434583.USD","LU1923623000.USD","LU0390134368.USD","LU0081259029.USD","LU1852331112.SGD","LU1880398471.USD","IE0004445239.USD","BK4139","LU0642271901.SGD","BK4605","BK4534","BK4566","LU1951198990.SGD","LU2264538146.SGD","LU1316542783.SGD","LU2054465674.USD","BK4575","LU2360106780.USD","OPT.AU","LU1880398554.USD","LU0127658192.USD","LU1242518857.USD"],"gpt_icon":1},{"id":"2523932385","title":"Opthea Ltd - Estimates Will Have Unaudited Cash and Cash Equivalents of US$100M at End of March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523932385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523932385?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:42","pubTimestamp":1743385329,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2523393238","title":"Opthea Ltd - There Remains Material Uncertainty as to Opthea's Ability to Continue as a Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2523393238","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523393238?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:42","pubTimestamp":1743385329,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OPT.AU"],"gpt_icon":0},{"id":"2522532974","title":"Why this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532974","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532974?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:30","pubTimestamp":1743107400,"startTime":"0","endTime":"0","summary":"ASX All Ords dividend stock Regal Partners Ltd  is having a wild ride this week. Shares in the All Ordinaries Index  listed alternative investment manager closed down 8.85% on Thursday at $2.37. That followed on a gain of 2.4% on Wednesday and a gain of 5.4% on Tuesday. All of which followed a painful 14.8% decline on Monday. Why the big fall in Regal Partners shares on Monday?Monday's big sell-off in the ASX All Ords dividend stock followed on concerning news from eye treatment company Opthea Limited . Opthea reported that its phase 3 COAST clinical trial had failed to meet its primary goal. And as the Motley Fool's Bronwyn Allen noted, \"The failure of the trial raises serious financial concerns for Opthea.\" Indeed, Opthea stated, \"In light of these matters, there remains material uncertainty as to Opthea's ability to continue as a going concern.\" So, why were investors selling Regal Partners shares on the news?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/28/why-this-sold-off-asx-all-ords-dividend-stock-is-well-placed-to-generate-long-term-shareholder-value/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","RPL.AU","BK4139","OPT","OPT.AU","BK7062","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2522894535","title":"Australian Shares Rise as Trump Signals Tariff Leniency; Endeavour to Undergo Overhaul as New Executive Chairman Leads Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2522894535","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522894535?lang=en_us&edition=fundamental","pubTime":"2025-03-26 13:59","pubTimestamp":1742968778,"startTime":"0","endTime":"0","summary":"Australian stocks rose on Wednesday as US President Trump signaled that his tariff plans would likely take a lenient approach.The S&P/ASX 200 Index rose 0.7% or 56.5 points to close at 7,999.Trump sai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PDN.AU","BK7509","BK7083","HM1.AU","XJO.AU","EDV.AU","BK7040","XAO.AU","BK7508","BK7067","OPT.AU","XKO.AU"],"gpt_icon":0},{"id":"2522083015","title":"HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522083015","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522083015?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:49","pubTimestamp":1742946561,"startTime":"0","endTime":"0","summary":"Hearts and Minds Investments  said its revaluation of the holding value of Opthea  in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.Opthea said Monday that its Combination OPT-302 with Aflibercept  study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.Shares of the company rose 1% in recent Wednesday trade.Price : $3.05, Change: $+0.040, Percent Change: +1.33%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OPT","NAV","HM1.AU","BK4139","BK7508","OPT.AU"],"gpt_icon":0},{"id":"2522072540","title":"Trading in Opthea Still Halted After Phase 3 Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2522072540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522072540?lang=en_us&edition=fundamental","pubTime":"2025-03-26 00:43","pubTimestamp":1742920980,"startTime":"0","endTime":"0","summary":"Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in wet age-related macular degeneration, or wet AMD.Opthea on Monday said the Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision, missed its primary endpoint of mean change in best corrected visual acuity.Opthea said it is considering the impact of the negative study results under its development funding agreement, adding that it may be required to pay amounts to the investors that would have a material adverse impact on its solvency, and that there is material uncertainty about its ability to continue as a going concern.The company said it is in talks with its development funding investors to determine the most appropriate course of action, and that it has requested that trading in its securities re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4512","BK4573","LU0127658192.USD","LU0823421416.USD","BK4529","IE00BMPRXR70.SGD","LU0082616367.USD","IE0009356076.USD","LU1303367103.USD","LU0109392836.USD","LU2250418816.HKD","LU1923623000.USD","LU1988902786.USD","OPT.AU","IE0004445239.USD","LU0719512351.SGD","BK4139","LU0390134368.USD","IE00BMPRXN33.USD","LU0823434740.USD","LU0889565833.HKD","LU0823421333.USD","LU1951200564.SGD","LU1989764664.SGD","LU2098885051.SGD","OPT","BK4614","LU1242518857.USD","LU1316542783.SGD","BK4534","BK4554","BK4588","LU0979878070.USD","LU2458330243.SGD","BK4575","LU2054465674.USD","BK4585","LU0056508442.USD","BK4566","LU2264538146.SGD","LU1803068979.SGD","BK4605","BK4612","LU1951198990.SGD","LU1064131342.USD","LU1852331112.SGD","BK4141","LU0823434583.USD"],"gpt_icon":1},{"id":"2522203520","title":"Opthea Ltd : H.c. Wainwright Cuts Target Price to $2 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2522203520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522203520?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:20","pubTimestamp":1742905248,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q814H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OPT.AU","BK7067","OPT","BK7508"],"gpt_icon":0},{"id":"2522054302","title":"BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2522054302","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522054302?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:36","pubTimestamp":1742873771,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake** Shares of Regal Asian Investments RG8.AX fall as much as 3.8% to A$1.915, their lowest level since Dec 8, 2023** Stock posts biggest intraday decline since Feb 20** Investment manager devalues stake in biotech Opthea OPT.AX to A$0.20/shr vs OPT's last close of A$0.60 before trading was suspended** OPT on Monday warned of insolvency after its late-stage trial for its wet age-related macular degeneration injection failed** RG8 stock last down 2%, bringing YTD losses to 8.9%.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL6N3Q806O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067","RG8.AU"],"gpt_icon":0},{"id":"2522594470","title":"Opthea Ltd : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2522594470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522594470?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:22","pubTimestamp":1742872926,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT","BK7067","OPT.AU","BK4139","BK7508"],"gpt_icon":0},{"id":"2522803268","title":"Regal Confirms Stake in Opthea","url":"https://stock-news.laohu8.com/highlight/detail?id=2522803268","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522803268?lang=en_us&edition=fundamental","pubTime":"2025-03-25 09:55","pubTimestamp":1742867733,"startTime":"0","endTime":"0","summary":"Regal Investment Fund  investment manager, Regal Funds Management, confirmed that it holds a 5.6% stake in Opthea  prior to the biopharmaceutical company's results of its study, according to a Tuesday filing with the Australian bourse.Opthea said Monday that its Combination OPT-302 with Aflibercept  study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","RF1.AU","BK7508","OPT","OPT.AU"],"gpt_icon":0},{"id":"2521561297","title":"Opthea Announces Coast Phase 3 Trial Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521561297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521561297?lang=en_us&edition=fundamental","pubTime":"2025-03-24 12:01","pubTimestamp":1742788860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA1HRPVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":74}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}